Efficacy and safety of onasemnogene abeparvovec for the treatment of patients with spinal muscular atrophy type 1: A systematic review with meta-analysis.

Fernandes BD, Krug BC, Rodrigues FD, Cirilo HNC, Borges SS, Schwartz IVD, Probst LF, Zimmermann I

Open source

DOI: 10.1371/journal.pone.0302860
Published: 2024
Container: PloS one
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1371/journal.pone.0302860,
  title = {Efficacy and safety of onasemnogene abeparvovec for the treatment of patients with spinal muscular atrophy type 1: A systematic review with meta-analysis.},
  author = {Fernandes BD and Krug BC and Rodrigues FD and Cirilo HNC and Borges SS and Schwartz IVD and Probst LF and Zimmermann I},
  year = {2024},
  journal = {PloS one},
  doi = {10.1371/journal.pone.0302860},
  url = {https://doi.org/10.1371/journal.pone.0302860}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of onasemnogene abeparvovec for the treatment of patients with spinal muscular atrophy type 1: A systematic review with meta-analysis.
AU  - Fernandes BD
AU  - Krug BC
AU  - Rodrigues FD
AU  - Cirilo HNC
AU  - Borges SS
AU  - Schwartz IVD
AU  - Probst LF
AU  - Zimmermann I
PY  - 2024
JO  - PloS one
DO  - 10.1371/journal.pone.0302860
UR  - https://doi.org/10.1371/journal.pone.0302860
ER  -

APA

BD, F., BC, K., FD, R., HNC, C., SS, B., IVD, S., LF, P., & I, Z. (2024). Efficacy and safety of onasemnogene abeparvovec for the treatment of patients with spinal muscular atrophy type 1: A systematic review with meta-analysis.. PloS one. https://doi.org/10.1371/journal.pone.0302860

Source records

pubmed · retrieved 2026-09-26T23:48:37.292Z
europe-pmc · retrieved 2026-09-26T23:48:37.299Z
doaj · retrieved 2026-09-26T23:48:37.320Z